Pfizer documents detail a deceptive case on Celebrex

Scouting thousands of pages of unsealed documents gathered in the securities fraud case prepared against Pfizer ($PFE), The New York Times reveals some embarrassing anecdotes from the pharma giant's internal records on Celebrex. Writing about a conference's decision to headline Celebrex data showing the arthritis drug was safer than standard remedies on the stomach, a research director wrote: "They swallowed our story, hook, line and sinker." That 'story' required a narrow look at the data. And a medical director at Pfizer called them out for "cherry-picking" the data. Report

 

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.